drugset / Trial / NCT05062876

A Study to Compare PK, PD and Safety of the AD-214 and AD-2141

NCT05062876

Phase 1 Completed 41 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 to AD-2141 in healthy volunteers.

Timeline

Start
2021-11-01
Primary completion
2022-03-17
Completion
2022-03-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator AD-214 Protein / enzyme biologic
Comparator AD-2141 Unknown